Establishing ctDNA as a validated primary surrogate endpoint
Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.
Outlook finally claims FDA approval for AMD drug
After three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US.
Argenx pens $2.2bn deal to buy autoimmune biotech Forte
Netherlands- and Belgium-based argenx has agreed to buy US biotech Forte Bio for up to $2.2bn, bolstering its autoimmune disease pipeline.
Ultomiris fail mars AZ's strong Q2 results
AstraZeneca has served up a robust set of interim results, leavened by strong sales of cancer drugs, but with some mixed pipeline news on the side.
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
The Evolution Summit Announces September 2026 Program for Cl...
Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.
Register Now for AAPS PharmSci 360!
Learn from pharmaceutical scientists involved at every stage of the drug development pipeline at PharmSci 360.
16th World Clinical Biomarkers & CDx Summit
The industry's flagship drug-CDx forum widening global precision medicine access.
Inizio Launches Intelligent Congress to Turn Event Investmen...
Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes